ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2025
Prevalence and Costs of Eosinophilic Esophagitis in the United States.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis: Inverse Association Between Helicobacter pylori Infection and Eosinophilic Oesophagitis.Alimentary pharmacology & therapeutics · 2025Pooled it
- Nasal and inhaled steroid use does not influence treatment response outcomes in eosinophilic esophagitis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026Article
- Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.Allergy · 2026Article
- Eosinophilic Oesophagitis Beyond the Oesophagus: High Prevalence of Chronic Rhinosinusitis-Type Symptoms and Their Impact on Symptom Severity in Swiss EoE Cohort Study Patients.Alimentary pharmacology & therapeutics · 2026Article
- Demographic Differences in Diagnosis of Eosinophilic Esophagitis: A Retrospective Analysis.Laryngoscope investigative otolaryngology · 2026Article
- Beyond the Surface: Exploring Altered Esophageal Distensibility and Compliance in Eosinophilic Esophagitis.Digestive diseases and sciences · 2026Review
- From Diet to Dysbiosis: The Microbiome's Relationship to Eosinophilic Esophagitis.Current gastroenterology reports · 2026Review
- Genetic variants associated with clinical characteristics and atopies in eosinophilic esophagitis.The journal of allergy and clinical immunology. Global · 2026Article
- Rumination syndrome and eosinophilic esophagitis in children: Defining the relationship.Journal of pediatric gastroenterology and nutrition · 2026Article
- Time Trends and Impact on Treatment Outcomes of Psychiatric Diagnoses in Patients with Eosinophilic Esophagitis.Journal of gastrointestinal and liver diseases : JGLD · 2026Article
- Prevalence and Costs of Non-esophageal Eosinophilic Gastrointestinal Diseases in the United States.Digestive diseases and sciences · 2026Article
- Multitrait analysis of genome-wide association studies expands eosinophilic esophagitis genetic susceptibility and polygenic risk scores.The Journal of allergy and clinical immunology · 2026Article
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Observational
- Bidirectional risk of autoimmune disease and eosinophilic esophagitis in Sweden.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- IL-13 and calpain-14 suppress the expression of SPINK7 by regulating OVOL1 in eosinophilic esophagitis.JCI insight · 2026Article
- Red Scare: Can the Occurrence of Food Impactions in Patients with Eosinophilic Esophagitis Help Guide Therapy?Digestive diseases and sciences · 2026Article
- Assessment, treatment, and prevention of complications in eosinophilic esophagitis.Foregut (Thousand Oaks, Calif.) · 2026Article
- Roles of systemic CD4Research square · 2026Article
- From esophagus to colon: A narrative review of eosinophilic gastrointestinal disorders.World journal of gastrointestinal pathophysiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND &
aimsEosinophilic esophagitis (EoE) has been continually increasing in prevalence, but current estimates are lacking. We aimed to determine updated estimates of the prevalence and medical costs associated with EoE in the United States (U.S.).
methodsWe used two large administrative databases, MarketScan and Medicare, and International Classification of Disease codes to calculate annual prevalence of EoE, as well as age- and sex-stratified estimates, standardized to the U.S. POPULATION: Health care utilization, including medications and endoscopic procedures, was quantified, and annual EoE-associated costs were estimated.
resultsWe identified 20,435 EoE cases in MarketScan in 2022 and 1913 EoE cases in Medicare in 2017. This translated to prevalences of 163.08 cases/100,000 and 64.83 cases/ 100,000 in MarketScan and Medicare, respectively. There was a 5-fold increase in prevalence in both databases since 2009. In MarketScan, prevalence was higher among males (204.45/100,000 vs 122.06/100,000 among females); for both sexes, peak prevalence was from 40 to 44 years of age. Standardized to the U.S. population, the prevalence of EoE was 142.5/100,000, extrapolating to 472,380 cases. Total EoE-associated health care costs were estimated to be $1.32 billion in 2024 dollars after accounting for inflation.
conclusionsThe prevalence of EoE continues to increase, with a rate of 1 in 617 in 2022 in those <65 years of age, and 1 in 1562 in 2017 those ≥65 years. Standardized to the U.S. population, the overall prevalence was approximately 1 in 700. EoE-associated annual costs were estimated to be $1.3 billion in 2024 dollars, representing a substantial financial burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.